The method could prove useful both for studying tumor immunology and in the development of cancer immunotherapies, said one of the researchers.
The partners will more thoroughly connect Protein Metrics' software suite and Sciex's high-resolution accurate mass (HRAM) spectrometry systems.
Gathering last week in Australia, the community continued its years-long push towards increased clinical relevance and integration with other omics disciplines.
The instrument's ability to run in negative-ion mode allows it to move beyond its traditional focus on proteins and into the analysis of other analyte classes.
Under the agreement, the companies plan to offer combined genetic and biochemical testing services out of Blueprint's clinical laboratory in Seattle.
The approach uses miniaturized sample prep and isobaric tagging and can identify up to 2,300 proteins in single cells and analyze around 100 cells per day.
Under the deal, Mobilion is implementing its SLIM ion mobility technology on Agilent's QTOF mass specs, with a broad commercial launch planned for 2021.
The South San Francisco, California cellular analysis firm alleges IonPath has infringed two patents and has been intereferening in its contracts.
Developed using the center's "industrialized" proteomics workflow, the panel identified patients up to a year before their diagnosis with 89 percent accuracy.
The partners plan to develop a number of liquid chromatography mass spectrometry methods for clinical research applications.
More powerful and user-friendly mass spec systems could drive an uptick in interest in the technique, suggested a leading top-down researcher.
The Tokyo-based firm said it will use the funding to support prototyping and commercialization of its mass spectrometry and optical spectroscopy instruments.
The study authors said that the technique could help researchers better prioritize which of the vast number of protein PTMs to investigate more thoroughly.
The company reported revenues of $490.2 million, up from $443.7 million in Q2 2018 and beating the consensus Wall Street estimate of $477.8 million.
The company's Q2 revenues were up less than 1 percent from $596.2 million in Q2 2018, and short of the average Wall Street estimate of $601.4 million.
The firm had revenues of $6.32 billion in Q2, up 4 percent from $6.08 billion last year and just beating the average Wall Street estimate of $6.3 billion.
The new partnership will support the analysis of glycans in 30,000 human samples by the end of 2021.
At the recent ASMS annual meeting, vendors including Bruker, Sciex, and Thermo Fisher Scientific presented new versions of the fast-growing mass spec technique.
Sciex will promote the Polly multi-omics platform in conjunction with its mass spectrometry instruments and differential ion mobility technologies.
The firm, Phenomix Sciences, anticipates that its test will help drive adoption of medications for obesity at a time when patients are reluctant to take them.
The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.
The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.
A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.